Correlation Between Galapagos and Design Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Galapagos and Design Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Galapagos and Design Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Galapagos NV ADR and Design Therapeutics, you can compare the effects of market volatilities on Galapagos and Design Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Galapagos with a short position of Design Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Galapagos and Design Therapeutics.

Diversification Opportunities for Galapagos and Design Therapeutics

-0.8
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Galapagos and Design is -0.8. Overlapping area represents the amount of risk that can be diversified away by holding Galapagos NV ADR and Design Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Design Therapeutics and Galapagos is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Galapagos NV ADR are associated (or correlated) with Design Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Design Therapeutics has no effect on the direction of Galapagos i.e., Galapagos and Design Therapeutics go up and down completely randomly.

Pair Corralation between Galapagos and Design Therapeutics

Given the investment horizon of 90 days Galapagos NV ADR is expected to under-perform the Design Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Galapagos NV ADR is 5.07 times less risky than Design Therapeutics. The stock trades about -0.13 of its potential returns per unit of risk. The Design Therapeutics is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  365.00  in Design Therapeutics on February 24, 2024 and sell it today you would earn a total of  38.00  from holding Design Therapeutics or generate 10.41% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Galapagos NV ADR  vs.  Design Therapeutics

 Performance 
       Timeline  
Galapagos NV ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Galapagos NV ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in June 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Design Therapeutics 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Design Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Design Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Galapagos and Design Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Galapagos and Design Therapeutics

The main advantage of trading using opposite Galapagos and Design Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Galapagos position performs unexpectedly, Design Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will offset losses from the drop in Design Therapeutics' long position.
The idea behind Galapagos NV ADR and Design Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance